BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 25985907)

  • 1. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
    Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
    Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
    Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
    Katzmann JL; Sorio-Vilela F; Dornstauder E; Fraas U; Smieszek T; Zappacosta S; Laufs U
    Clin Res Cardiol; 2022 Mar; 111(3):243-252. PubMed ID: 32949286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Simonyi G
    Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
    Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis.
    Mikhailidis DP; Lawson RW; McCormick AL; Sibbring GC; Tershakovec AM; Davies GM; Tunceli K
    Curr Med Res Opin; 2011 Jun; 27(6):1191-210. PubMed ID: 21473671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
    Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
    Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
    Japaridze L; Sadunishvili M; Megreladze I
    Georgian Med News; 2016 Mar; (252):15-22. PubMed ID: 27119829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.